Cumambrin B Alleviates Acute Lung Injury In Vivo and Attenuates NF‐κB/MAPK‐Mediated Inflammation and Oxidative Stress by Regulating the Accumulation of ROS In Vitro
Archiv der Pharmazie · 2025
DOI: 10.1002/ardp.70137 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archiv der Pharmazie, 2025. Verfasst von Qianqian Ren und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Chemistry and Chemical Engineering, Anhui University of Technology, Anhui, People's Republic of China. Hauptthemen laut MEDLINE: Acute Lung Injury, Oxidative Stress, Reactive Oxygen Species, Anti-Inflammatory Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: The present study was funded by the Science and Technology Project of Ma'anshan City under (2022KN-11), Natural Science Foundation of Zhejiang Province (LQ22H2….
Abstract (Originalsprache)
Acute lung injury (ALI) represents a critical medical issue typified by serious respiratory dysfunction, which frequently progresses to acute respiratory distress syndrome (ARDS), a condition linked to elevated rates of morbidity and mortality. In the present research, cumambrin B (CB), a sesquiterpene lactone extracted from Ajania fruticulosa (Ledeb.) Poljak was systematically examined, focusing on its potential anti‐inflammatory molecular mechanism and therapeutic efficacy in ALI models. In vitro, lipopolysaccharide (LPS) was demonstrated to activate nuclear factor kappa B (NF‐κB) or mitogen‐activated protein kinase (MAPK) pathways in RAW264.7 macrophages, triggering protein phosphorylation. Conversely, treatment with CB selectively suppressed phosphorylation events and inhibited the initiation of these pathways. In vivo, CB ameliorated LPS‐induced pathological alterations, including alveolar wall thickening and parenchymal structural disruption. Further analysis demonstrated that CB pretreatment alleviated LPS‐induced pulmonary edema, as substantiated by a reduced pulmonary wet‐to‐dry ratio, and mitigated lung inflammation, indicated by decreased interleukin 6 (IL‐6) mRNA expression in lung tissue, lower IL‐6 levels, reduced leukocyte counts, and diminished bronchoalveolar lavage fluid (BALF) content of total protein in mice. Conclusively, our research indicates that CB exhibits potential as a viable pharmaceutical agent for managing inflammatory conditions, such as ALI.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Chemistry and Chemical Engineering, Anhui University of Technology, Anhui, People's Republic of China.
- College of Life Sciences, Shanghai Normal University, Shanghai, People's Republic of China.
- School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, People's Republic of China.
Förderung
- The present study was funded by the Science and Technology Project of Ma'anshan City under (2022KN-11), Natural Science Foundation of Zhejiang Province (LQ22H2…
Zitieren
APA
Ren, Q., Que, Y., Min, X., Mu, W., Ruan, D., Wang, P., Dai, X., Cao, J., Yang, Y., & Huang, G. (2025). Cumambrin B Alleviates Acute Lung Injury In Vivo and Attenuates NF‐κB/MAPK‐Mediated Inflammation and Oxidative Stress by Regulating the Accumulation of ROS In Vitro. Archiv der Pharmazie. https://doi.org/10.1002/ardp.70137
Vancouver
Ren Q, Que Y, Min X, Mu W, Ruan D, Wang P, et al. Cumambrin B Alleviates Acute Lung Injury In Vivo and Attenuates NF‐κB/MAPK‐Mediated Inflammation and Oxidative Stress by Regulating the Accumulation of ROS In Vitro. Archiv der Pharmazie. 2025. doi:10.1002/ardp.70137
BibTeX
@article{Ren2025,
author = {Ren, Qianqian and Que, Yuemei and Min, Xiaoran and Mu, Wenhao and Ruan, Dandan and Wang, Peixing and Dai, Xiling and Cao, Jianguo and Yang, Yanzi and Huang, Guozheng},
title = {Cumambrin B Alleviates Acute Lung Injury In Vivo and Attenuates NF‐κB/MAPK‐Mediated Inflammation and Oxidative Stress by Regulating the Accumulation of ROS In Vitro},
journal = {Archiv der Pharmazie},
year = {2025},
doi = {10.1002/ardp.70137}
}
EUVIMED